Signed Sales Consignment Agreement for WAYMED ENDO

Strengthening Gastroenterology Business Portfolio

Building a 'Total Solution' by Adding AI Diagnostic Support to Fexuclu and Cleancol

Expanding Distribution to Tertiary Hospitals and

On July 10, Daewoong Pharmaceutical announced that it had signed a sales consignment agreement with Wison, a medical artificial intelligence (AI) specialist company, for the AI endoscopic image analysis software 'WAYMED ENDO', as part of its efforts to expand its digital healthcare business.


Daewoong Pharmaceutical CEO Changjae Lee (right) and Wisen CEO Kyungnam Kim (left) are posing for a commemorative photo after signing the contract. Daewoong Pharmaceutical

Daewoong Pharmaceutical CEO Changjae Lee (right) and Wisen CEO Kyungnam Kim (left) are posing for a commemorative photo after signing the contract. Daewoong Pharmaceutical

View original image

Through this agreement, Daewoong Pharmaceutical will add the AI-powered endoscopic diagnostic support software to its existing gastroenterology product lineup, which includes the gastroesophageal reflux disease treatment 'Fexuclu' and the colon cleansing agent 'Cleancol'. The company plans to establish a 'total solution for digestive diseases' that covers everything from examination preparation to diagnostic assistance and treatment.


The two companies will collaborate to expand the domestic supply of WAYMED ENDO. Daewoong Pharmaceutical will leverage its nationwide hospital sales network to handle sales and marketing to tertiary hospitals, general hospitals, health checkup centers, and clinics, while Wison will be responsible for product enhancement and technical support.


WAYMED ENDO is an AI-based real-time image analysis software for upper and lower gastrointestinal endoscopy. It assists in detecting lesions that are easily missed by the naked eye during endoscopy, such as those behind folds, at the edges, or small lesions measuring 2 to 3 mm. The AI also automatically measures key endoscopy quality indicators, such as examination time and withdrawal time, supporting quality control and improving work efficiency for medical professionals.


The company explained that this product is compatible with various endoscopy equipment, allowing existing medical infrastructure to be utilized and reducing the need to replace devices. In July 2023, it was designated as the 37th innovative medical device by the Ministry of Food and Drug Safety, and is currently being used in medical institutions both in Korea and abroad.


Changjae Lee, CEO of Daewoong Pharmaceutical, stated, "This collaboration marks the starting point for expanding our digital healthcare business into the field of digestive diseases. Based on our existing product lineup and nationwide hospital network, we will expand the supply of WAYMED ENDO and support improvements in the examination environment and work efficiency for medical professionals."



Kyungnam Kim, CEO of Wison, said, "The partnership with Daewoong Pharmaceutical will be an important milestone for the expansion of the AI endoscopy market in Korea. We will continue to focus on product development and technological advancement so that more medical institutions can utilize AI-based endoscopic diagnostic support software."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing